Loading...

Omnicell

DB:OC9
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OC9
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • Omnicell has significant price volatility in the past 3 months.
OC9 Share Price and Events
7 Day Returns
-0.2%
DB:OC9
2.7%
DE Healthcare Services
2.1%
DE Market
1 Year Returns
112.9%
DB:OC9
15.7%
DE Healthcare Services
-7.6%
DE Market
OC9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Omnicell (OC9) -0.2% 0.3% 38.5% 112.9% 214% 249.7%
DE Healthcare Services 2.7% 3.7% 23.3% 15.7% 43.4% 158.8%
DE Market 2.1% 3.6% 8.1% -7.6% 9.8% 12.4%
1 Year Return vs Industry and Market
  • OC9 outperformed the Healthcare Services industry which returned 15.7% over the past year.
  • OC9 outperformed the Market in Germany which returned -7.6% over the past year.
Price Volatility
OC9
Industry
5yr Volatility vs Market
Related Companies

OC9 Value

 Is Omnicell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Omnicell to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Omnicell.

DB:OC9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:OC9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.22
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.222 (1 + (1- 21%) (3.93%))
1.174
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.17
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.174 * 5.96%)
7.23%

Discounted Cash Flow Calculation for DB:OC9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Omnicell is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:OC9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.23%)
2019 80.17 Analyst x3 74.77
2020 86.86 Analyst x2 75.54
2021 107.62 Analyst x1 87.29
2022 125.88 Analyst x1 95.22
2023 147.98 Analyst x1 104.39
2024 164.81 Est @ 11.38% 108.43
2025 178.05 Est @ 8.03% 109.24
2026 188.18 Est @ 5.69% 107.68
2027 195.80 Est @ 4.05% 104.49
2028 201.49 Est @ 2.9% 100.27
Present value of next 10 years cash flows $967.32
DB:OC9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $201.49 × (1 + 0.23%) ÷ (7.23% – 0.23%)
$2,885.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,885.18 ÷ (1 + 7.23%)10
$1,435.85
DB:OC9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $967.32 + $1,435.85
$2,403.17
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,403.17 / 40.80
$58.9
DB:OC9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:OC9 represents 0.89043x of NasdaqGS:OMCL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89043x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 58.90 x 0.89043
€52.45
Value per share (EUR) From above. €52.45
Current discount Discount to share price of €73.71
= -1 x (€73.71 - €52.45) / €52.45
-40.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Omnicell is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Omnicell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Omnicell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OC9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.96
NasdaqGS:OMCL Share Price ** NasdaqGS (2019-03-20) in USD $82.78
Europe Healthcare Services Industry PE Ratio Median Figure of 17 Publicly-Listed Healthcare Services Companies 27.96x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.91x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Omnicell.

DB:OC9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OMCL Share Price ÷ EPS (both in USD)

= 82.78 ÷ 0.96

86.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Omnicell is overvalued based on earnings compared to the Europe Healthcare Services industry average.
  • Omnicell is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Omnicell's expected growth come at a high price?
Raw Data
DB:OC9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 86.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
29.9%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 1.98x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:OC9 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 86.1x ÷ 29.9%

2.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Omnicell is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Omnicell's assets?
Raw Data
DB:OC9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $16.85
NasdaqGS:OMCL Share Price * NasdaqGS (2019-03-20) in USD $82.78
Germany Healthcare Services Industry PB Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 2.76x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.79x
DB:OC9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OMCL Share Price ÷ Book Value per Share (both in USD)

= 82.78 ÷ 16.85

4.91x

* Primary Listing of Omnicell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Omnicell is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Omnicell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Omnicell has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OC9 Future Performance

 How is Omnicell expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Omnicell expected to grow at an attractive rate?
  • Omnicell's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Omnicell's earnings growth is expected to exceed the Germany market average.
  • Omnicell's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:OC9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OC9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 29.9%
DB:OC9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 10.2%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 15.2%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OC9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OC9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,361 2
2022-12-31 1,215 2
2021-12-31 1,054 3
2020-12-31 978 99 70 8
2019-12-31 890 101 56 8
DB:OC9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 787 104 38
2018-09-30 775 61 44
2018-06-30 758 27 38
2018-03-31 750 16 34
2017-12-31 713 25 31
2017-09-30 688 45 -1
2017-06-30 678 72 -6
2017-03-31 670 56 -9
2016-12-31 696 50 10
2016-09-30 651 54 8
2016-06-30 599 40 14
2016-03-31 539 44 24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Omnicell's earnings are expected to grow significantly at over 20% yearly.
  • Omnicell's revenue is expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OC9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Omnicell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OC9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 1.64 1.86 1.48 6.00
2019-12-31 1.33 1.47 1.10 6.00
DB:OC9 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.96
2018-09-30 1.14
2018-06-30 1.00
2018-03-31 0.89
2017-12-31 0.81
2017-09-30 -0.01
2017-06-30 -0.17
2017-03-31 -0.26
2016-12-31 0.27
2016-09-30 0.23
2016-06-30 0.40
2016-03-31 0.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Omnicell is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Omnicell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Omnicell has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OC9 Past Performance

  How has Omnicell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Omnicell's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Omnicell's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Omnicell's 1-year earnings growth exceeds its 5-year average (23.6% vs -1.7%)
  • Omnicell's earnings growth has exceeded the Europe Healthcare Services industry average in the past year (23.6% vs 11.5%).
Earnings and Revenue History
Omnicell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Omnicell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OC9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 787.31 37.73 263.10 64.84
2018-09-30 775.38 44.25 267.07 63.75
2018-06-30 757.86 38.37 257.67 64.36
2018-03-31 750.23 33.66 253.66 66.56
2017-12-31 712.71 30.52 241.47 66.02
2017-09-30 688.32 -0.55 233.28 65.03
2017-06-30 678.31 -6.32 238.39 63.88
2017-03-31 670.17 -9.35 242.51 59.96
2016-12-31 695.91 9.76 229.78 57.80
2016-09-30 650.96 8.10 230.90 52.12
2016-06-30 599.46 14.15 210.26 46.03
2016-03-31 539.34 24.06 183.95 40.98
2015-12-31 484.56 30.76 164.68 35.16
2015-09-30 475.78 32.34 165.86 34.07
2015-06-30 463.09 31.60 164.07 31.98
2015-03-31 455.36 30.64 161.34 29.70
2014-12-31 440.90 30.52 156.48 27.80
2014-09-30 425.11 28.11 149.23 26.81
2014-06-30 406.61 28.56 145.12 26.29
2014-03-31 395.24 26.79 140.97 26.97
2013-12-31 380.59 23.98 139.00 27.31
2013-09-30 365.00 22.69 135.12 26.09
2013-06-30 355.30 21.85 129.67 25.08
2013-03-31 336.99 17.21 125.06 23.43
2012-12-31 314.03 16.18 119.74 23.73
2012-09-30 286.79 14.78 105.99 23.44
2012-06-30 266.90 10.86 100.31 23.92
2012-03-31 252.52 12.07 97.86 23.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Omnicell has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Omnicell used its assets less efficiently than the Europe Healthcare Services industry average last year based on Return on Assets.
  • Omnicell's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Omnicell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Omnicell has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OC9 Health

 How is Omnicell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Omnicell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Omnicell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Omnicell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Omnicell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Omnicell Company Filings, last reported 2 months ago.

DB:OC9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 679.62 135.42 67.19
2018-09-30 619.24 184.84 44.17
2018-06-30 588.64 198.77 46.17
2018-03-31 574.50 208.20 43.77
2017-12-31 554.34 210.13 32.42
2017-09-30 472.50 192.33 7.47
2017-06-30 449.50 194.44 26.94
2017-03-31 438.94 214.54 46.35
2016-12-31 431.61 254.14 54.49
2016-09-30 427.57 223.24 47.29
2016-06-30 413.20 225.35 41.03
2016-03-31 410.51 227.46 53.49
2015-12-31 402.39 0.00 82.22
2015-09-30 391.54 0.00 57.76
2015-06-30 399.35 0.00 88.03
2015-03-31 405.45 0.00 139.55
2014-12-31 390.10 0.00 125.89
2014-09-30 378.90 0.00 104.19
2014-06-30 377.62 0.00 126.38
2014-03-31 365.18 0.00 107.56
2013-12-31 349.00 0.00 104.53
2013-09-30 357.79 0.00 116.19
2013-06-30 333.73 0.00 87.33
2013-03-31 321.79 0.00 69.82
2012-12-31 307.55 0.00 62.31
2012-09-30 296.51 0.00 54.82
2012-06-30 287.52 0.00 54.07
2012-03-31 290.89 0.00 209.54
  • Omnicell's level of debt (19.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 19.9% today).
  • Debt is well covered by operating cash flow (76.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
X
Financial health checks
We assess Omnicell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Omnicell has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OC9 Dividends

 What is Omnicell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Omnicell dividends.
If you bought €2,000 of Omnicell shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Omnicell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Omnicell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OC9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OC9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Omnicell has not reported any payouts.
  • Unable to verify if Omnicell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Omnicell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Omnicell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Omnicell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Omnicell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Omnicell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OC9 Management

 What is the CEO of Omnicell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Randy Lipps
COMPENSATION $5,089,721
AGE 61
TENURE AS CEO 16.4 years
CEO Bio

Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps had been Executive Chairman and Executive Director of Omnicell, Inc. since September 1992. He serves as a General Partner at Launchpad Digital Health LLC. Previously, Mr. Lipps served as the Senior Vice President of ST. Holdings Inc. from 1989 to 1992. He served as an Assistant Vice President of Sales & Operations for a subsidiary of AMR, the parent company of American Airlines, Inc. from 1987 to 1989. He has more than 25 years of experience in healthcare information technology. He serves as a Director of imPower Health, Inc. Mr. Lipps serves as a Member of Advisory Board of Launchpad Digital Health. He served as an Independent Director at Invuity, Inc since June 2013 until October 22, 2018. He has been a Director of Radisphere National Radiology Group since November 2011. Mr. Lipps received both a B.S. in Economics and a BBA from Southern Methodist University.

CEO Compensation
  • Randy's compensation has increased by more than 20% in the past year.
  • Randy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Omnicell management team in years:

3.3
Average Tenure
56
Average Age
  • The tenure for the Omnicell management team is about average.
Management Team

Randy Lipps

TITLE
Founder
COMPENSATION
$5M
AGE
61
TENURE
16.4 yrs

Peter Kuipers

TITLE
Executive VP & CFO
COMPENSATION
$2M
AGE
46
TENURE
3.6 yrs

Dan Johnston

TITLE
Executive VP
COMPENSATION
$1M
AGE
54
TENURE
4.1 yrs

Rob Seim

TITLE
President of Global Automation & Medication Adherence
COMPENSATION
$2M
AGE
58
TENURE
3 yrs

Joe Spears

TITLE
VP of Corporate Finance & Chief Accounting Officer
AGE
58
TENURE
1.4 yrs

Nhat Ngo

TITLE
Executive VP of Marketing
COMPENSATION
$1M
AGE
45
TENURE
1.2 yrs

Jorge Taborga

TITLE
Executive Vice President of Engineering & Integration Management Officer
AGE
59
TENURE
11.7 yrs

Scott Seidelmann

TITLE
Executive VP & Chief Commercial Officer
AGE
42
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Omnicell board of directors in years:

6.8
Average Tenure
62.5
Average Age
  • The tenure for the Omnicell board of directors is about average.
Board of Directors

Randy Lipps

TITLE
Founder
COMPENSATION
$5M
AGE
61
TENURE
26.5 yrs

Sara White

TITLE
Independent Director
COMPENSATION
$252K
AGE
72
TENURE
15.9 yrs

Jim Judson

TITLE
Lead Independent Director
COMPENSATION
$289K
AGE
63

Gary Petersmeyer

TITLE
Independent Director
COMPENSATION
$274K
AGE
71
TENURE
12.2 yrs

Joanne Bauer

TITLE
Independent Director
COMPENSATION
$234K
AGE
62
TENURE
5.2 yrs

Vance Moore

TITLE
Independent Director
COMPENSATION
$230K
AGE
57
TENURE
6.8 yrs

Mark Parrish

TITLE
Independent Director
COMPENSATION
$214K
AGE
62
TENURE
6.2 yrs

Bruce Smith

TITLE
Independent Director
COMPENSATION
$225K
AGE
70
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • Omnicell insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Mar 19 Sell Jorge Taborga Individual 12. Mar 19 12. Mar 19 -1,132 €74.13 €-83,914
04. Mar 19 Sell Joseph Spears Individual 01. Mar 19 01. Mar 19 -2,846 €74.95 €-213,310
22. Feb 19 Sell Randall Lipps Individual 22. Feb 19 22. Feb 19 -20,000 €75.70 €-1,508,667
16. Feb 19 Sell Gary Petersmeyer Individual 15. Feb 19 15. Feb 19 -1,000 €72.96 €-72,962
12. Feb 19 Sell Gary Petersmeyer Individual 12. Feb 19 12. Feb 19 -750 €69.70 €-52,275
05. Jul 18 Sell Nhat Ngo Individual 05. Jul 18 05. Jul 18 -20,436 €47.01 €-960,666
20. Jun 18 Sell Nhat Ngo Individual 19. Jun 18 19. Jun 18 -4,114 €44.92 €-184,807
17. May 18 Sell Gary Petersmeyer Individual 17. May 18 17. May 18 -1,650 €39.10 €-64,515
X
Management checks
We assess Omnicell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Omnicell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OC9 News

Simply Wall St News

OC9 Company Info

Description

Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility’s in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Details
Name: Omnicell, Inc.
OC9
Exchange: DB
Founded: 1992
$3,034,442,960
40,799,170
Website: http://www.omnicell.com
Address: Omnicell, Inc.
590 East Middlefield Road,
Mountain View,
California, 94043,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OMCL Common Stock Nasdaq Global Select US USD 07. Aug 2001
DB OC9 Common Stock Deutsche Boerse AG DE EUR 07. Aug 2001
Number of employees
Current staff
Staff numbers
2,480
Omnicell employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 21:36
End of day share price update: 2019/03/20 00:00
Last estimates confirmation: 2019/03/08
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.